Latest news with #Zefylti™
Business Upturn
02-07-2025
- Business
- Business Upturn
Aurobindo Pharma's subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys'
Aurobindo Pharma's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzumab biosimilar. This approval follows the positive opinion issued by the European Medicines Agency's (EMA) CHMP in April 2025, recommending the product for authorization. Dazublys™ is a biosimilar of trastuzumab, a widely used monoclonal antibody in the treatment of HER2-positive breast and gastric cancers. With this latest approval, Dazublys™ becomes CuraTeQ's third EMA-approved biosimilar, following Dyrupeg™ (approved in April 2025) and Zefylti™ (approved in February 2025). It also marks the fourth biosimilar approval for CuraTeQ in the European region, including Bevqolva™, which received a green light from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in December 2024. This continued string of regulatory successes further strengthens Aurobindo Pharma's global biosimilar portfolio and underscores the company's commitment to expanding access to high-quality, affordable biologics in key regulated markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
24-06-2025
- Business
- Business Upturn
Aurobindo Pharma's CuraTeQ secures UK's MHRA approval for Dyrupeg
By Aman Shukla Published on June 24, 2025, 16:58 IST CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™ , a biosimilar of pegylated filgrastim. This marks the company's third biosimilar approval in the UK, following Bevqolva™ in December 2024 and Zefylti™ in May 2025. The latest approval adds to Dyrupeg's regulatory success, as it had already secured a marketing nod from the European Commission (EC) in April 2025. Pegylated filgrastim is commonly used to reduce infection risk in cancer patients undergoing chemotherapy, and the launch of Dyrupeg™ is expected to enhance patient access to affordable biologic therapies across Europe and the UK. In the exchange filing, the compamy shared, 'CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg™ received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ's third biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025.' With this milestone, CuraTeQ continues to strengthen its biosimilar portfolio and expand its footprint in the global biopharmaceutical market. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
